🇺🇸 FDA
Pipeline program

PRO045, 0.15 mg/kg/week

PRO045-CLIN-01

Phase 2 small_molecule terminated

Quick answer

PRO045, 0.15 mg/kg/week for Duchenne Muscular Dystrophy is a Phase 2 program (small_molecule) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).

Program details

Company
BIOMARIN PHARMACEUTICAL INC
Indication
Duchenne Muscular Dystrophy
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials